Citations

Clear

431 citation(s) found for "Schmidt, B".

Joint associations of a polygenic risk score and environmental risk factors for breast cancer in the Breast Cancer Association Consortium
Song, Minsun , Brook, Mark N. , Michailidou, Kyriaki , Bolla, Manjeet K. , Wang, Qin , Wilcox, Amber N, Hopper, John L. , Keeman, Renske , Fasching, Peter A. , Beckmann, Matthias W. , Gago-Domínguez, Manuela , Castelao, Jose E. , Guénel, Pascal , Truong, Thérèse , Bojesen, Stig E. , Flyger, Henrik, Brenner, Hermann , Brauch, Hiltrud , Brüning, Thomas , Mannermaa, Arto, Kosma, Veli-Matti, Lambrechts, Diether , Keupers, Machteld , Couch, Fergus J. , Vachon, Celine M. , MacInnis, Robert J. , Figueroa, Jonine D. , Brinton, Louise A. , Brand, Judith S. , Gabrielson, Marike , Humphreys, Keith , Orr, Nick , Swerdlow, Anthony J. , Easton, Douglas F. , Chatterjee, Nilanjan , Chang‐Claude, Jenny , García‐Closas, Montserrat , Lambrechts, Diether , Wilcox, Amber N , Vachon, Celine, Lambrechts, Diether , Swerdlow, Anthony J , Maclnnis, Robert , Lambrechts, Diether , Brenner, Hermann , Gago-Dominguez, Manuela , Guénel, Pascal , García-Closas, Montserrat , Michailidou, Kyriaki , Figueroa, Jonine D , Gabrielson, Marike , Rudolph, Anja , Milne, Roger L. , Mavaddat, Nasim , Dennis, Joe , Hurson, Amber N. , Southey, Melissa C. , Arndt, Volker , Mannermaa, Arto, Couch, Fergus J. , Vachon, Celine M. , Giles, Graham G. , Czene, Kamila , Cox, Angela , Cross, Simon S. , Dunning, Alison M. , Hall, Per N , Pharoah, Paul D.P. , Schmidt, Marjanka K. , Bojesen, Stig E , Truong, Therese , Brauch, Hiltrud , Orr, Nick

Mayo Clinic

International Journal of Epidemiology | November 23, 2017 | Volume: 47 | Issue: 2 | Pages: 526-536

10.1093/ije/dyx242 | PMID 29315403 Get It

Impact of Excessive Weight Gain on Cardiovascular Outcomes in Type 1 Diabetes: Results From the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study
Purnell, Jonathan Q. , Braffett, Barbara H. , Zinman, Bernard, Gubitosi‐Klug, Rose , Sivitz, William, Bantle, John P., Ziegler, Georgia, Cleary, Patricia A., Brunzell, John D. , Nathan, D.M., Zinman, B., Crofford, O., Genuth, S., Brown-Friday, J., Crandall, J., Engel, S., Martinez, H., Phillips, M., Reid, M., Shamoon, H., Sheindlin, J., Gubitosi-Klug, R., Mayer, L., Pendegast, S., Zegarra, H., Miller, D., Singerman, L., Smith-Brewer, S., Novak, M., Quin, J., Genuth, Saul, Palmert, M., Brown, E., McConnell, J., Pugsley, P., Crawford, P., Dahms, W., Gregory, N.S., Lackaye, M.E., Kiss, S., Chan, R., Orlin, A., Rubin, M., Brillon, D., Reppucci, V., Lee, T., Heinemann, M., Chang, S., Levy, B., Jovanovic, L., Richardson, M., Bosco, B., Dwoskin, A., Hanna, R., Barron, S., Campbell, R., Bhan, A., Krüger, D., Jones, J.K., Edwards, P.A., Bhan, A., Carey, J.D., Angus, E., Thomas, A., Galprin, A., McLellan, M., Whitehouse, F., Bergenstal, R., Johnson, M., Gunyou, K., Thomas, L., Laechelt, J., Hollander, P., Spencer, M., Kendall, D., Cuddihy, R., Callahan, P., List, S., Gott, J., Rude, N., Olson, B., Franz, M., Castle, G., Birk, R., Nelson, J., Freking, D., Gill, L., Mestrezat, W., Etzwiler, D., Morgan, K., Aiello, L.P., Golden, E., Arrigg, P., Asuquo, V., Beaser, R., Bestourous, L., Cavallerano, J., Cavicchi, R., Ganda, O., Hamdy, O., Kirby, R., Murtha, T., Schlossman, D., Shah, S., Sharuk, G., Silver, P., Silver, P., Stockman, M., Sun, J., Weimann, E., Wolpert, H., Aiello, L. M., Jacobson, A., Rand, L., Rosenzwieg, J., Nathan, D.M., Larkin, M.E., Christofi, M., Folino, K., Godine, J., Lou, P., Stevens, C., Anderson, E., Bode, H., Brink, S., Cornish, C., Cros, D., Delahanty, L., deManbey, A., Haggan, C., Lynch, J., McKitrick, C., Norman, D., Moore, D., Ong, M., Taylor, C., Zimbler, D., Crowell, S., Fritz, S., Hansen, K., Gauthier‐Kelly, C., Service, F. J., Ziegler, G., Barkmeier, A., Schmidt, L., French, B., Woodwick, R., Rizza, R., Schwenk, W. F., Haymond, M., Pach, J., Mortenson, J., Zimmerman, B., Lucas, A., Colligan, R., Luttrell, L., Lopes-Virella, M., Caulder, S., Pittman, C., Patel, N., Lee, K., Nutaitis, M., Fernandes, J., Hermayer, K., Kwon, S., Blevins, A., Parker, J., Colwell, J., Lee, D., Soule, J., Lindsey, P., Bracey, M., Farr, A., Elsing, S., Thompson, T., Selby, J., Lyons, T., Yacoub-Wasef, S., Szpiech, M., Wood, D., Mayfield, R., Molitch, M., Adelman, D., Colson, S., Jampol, L., Lyon, A., Gill, M., Strugula, Z., Kaminski, L., MIRZA, R., Simjanoski, E., Ryan, D., Johnson, C., Wallia, A., Ajroud-Driss, S., Astelford, P., Leloudes, N., Degillio, A., Schaefer, B., Mudaliar, S., Lorenzi, G., Goldbaum, M., Jones, K., Prince, M., Swenson, M., Grant, I., Reed, R., Lyon, R., Kolterman, O., Giotta, M, Clark, T., Friedenberg, G., Sivitz, W.I., Vittetoe, B., Kramer, J., Bayless, M., Zeitler, R., Schrott, H., Olson, N., Snetselaar, L., Hoffman, R., MacIndoe, J., Weingeist, T., Fountain, C., Miller, R., Johnsonbaugh, S., Patronas, M., Carney, M., Mendley, S., Salemi, P., Liss, R., Hebdon, M., Counts, D., Donner, T., Gordon, J., Hemady, R., Kowarski, A., Ostrowski, D., Steidl, S., Jones, B., Herman, W.H., Martin, C.L., Pop-Busui, R., Greene, D. A., Stevens, M.J., Burkhart, N., Sandford, T, Floyd, J., Bantle, J., Flaherty, N., Terry, J., Koozekanani, D., Montezuma, S., Wimmergren, N., Rogness, B., Mech, M., Strand, T., Olson, J., McKenzie, L., Kwong, C., Goetz, F., Warhol, R., Hainsworth, D., Goldstein, D., Hitt, S., Giangiacomo, J., Schade, D.S., Canady, J.L., Burge, M. R., Das, A., Avery, R.B., Ketai, L.H., Chapin, J.E., Schluter, M.L, Rich, J., Johannes, C., Hornbeck, D., Schutta, M., Bourne, P.A., Brucker, A., Braunstein, S., Schwartz, S., Maschak-Carey, B. J., Baker, L., Orchard, T., Cimino, L., Songer, T., Doft, B., Olson, S., Becker, D., Rubinstein, D., Bergren, R.L., Fruit, J., Hyre, R., Palmer, C., Silvers, N., Lobes, L., Rath, P. Paczan, Conrad, P. W., Yalamanchi, S., Wesche, J., Bratkowksi, M., Arslanian, S., Rinkoff, J., Warnicki, J., Curtin, D., Steinberg, D., Vagstad, G., Harris, R., Steranchak, L., Arch, J., Kelly, K., Ostrosaka, P., Guiliani, M., Good, M., Williams, T., Olsen, K., Campbell, A., Shipe, C., Conwit, R., Finegold, D., Zaucha, M., Drash, A., Morrison, A., Malone, J.I., Bernal, M.L., Pavan, P. R., Grove, N., Tanaka, E.A., McMillan, D., Vaccaro‐Kish, J., Babbione, L., Solc, H., DeClue, T.J., Dagogo-Jack, S., Wigley, C., Ricks, H., Kitabchi, A., Chaum, E., Murphy, M.B., Moser, S., Meyer, D., Iannacone, A., Yoser, S., Bryer‐Ash, M., Schüßler, S., Lambeth, H., Raskin, P., Strowig, S., Basco, M., Cercone, S., Zinman, B., Barnie, A., Devenyi, R., Mandelcorn, M., Brent, M., Rogers, S., Gordon, A., Bakshi, N., Perkins, B., Tuason, L., Perdikaris, F., Ehrlich, R., Daneman, D., Perlman, K., Ferguson, S., Palmer, J., Fahlstrom, R., Boer, I.H.de, Kinyoun, J., Ottingham, L. Van, Catton, S., Ginsberg, J., McDonald, C., Harth, J., Driscoll, M., Sheidow, T., Mahon, J., Canny, C., Nicolle, D., Colby, P., Dupre, J., Hramiak, I., Rodger, NW, Jenner, M., Smith, T., Brown, W., May, M., Hagan, J. Lipps, Agarwal, A., Adkins, T., Lorenz, R., Feman, S., Survant, L., White, N. H., Levandoski, L., Grand, G., Thomas, M., Joseph, D., Blinder, K., Shah, G., Burgess, D., Boniuk, I., Santiago, J., Tamborlane, W., Gatcomb, P., Stoessel, K., Ramos, P., Fong, K., Ossorio, P., Ahern, J., Meadema-Mayer, L., Beck, C., Farrell, K., Quin, J., Gaston, P., Trail, R., Lachin, J., Backlund, J., Bebu, I., Braffett, B., Diminick, L., Gao, X., Hsu, W., Klumpp, K., Trapani, Victoria R., Trapani, V., Cleary, P., McGee, P., Sun, W. , Villavicencio, S., Anderson, K., Dews, L., Younes, Naji , Rutledge, B., Chan, K., Rosenberg, D. , Petty, B., Determan, A., Kenny, D., Williams, C., Cowie, C., Siebert, C., Steffes, M., Arends, V., Bucksa, J., Nowicki, M., Chavers, B., O’Leary, D., Polák, J. (Jaroslav), Harrington, A., Funk, L., Crow, R., Gloeb, B., Thomas, S., O’Donnell, C., Soliman, EZ, Zhang, Z.M., Li, Y., Campbell, C., Keasler, L., Hensley, S., Hu, J., Barr, M., Taylor, T., Prineas, R., Feldman, E.L., Albers, J.W., Low, P., Sommer, C., Nickander, K., Speigelberg, T., Pfiefer, M., Schumer, M., Moran, M., Farquhar, J., Ryan, C., Sandstrom, D., Geckle, M., Cupelli, E., Thoma, F., Burzuk, B., Woodfill, T., Danis, R., Blodi, B., Lawrence, D., Wabers, H., Gangaputra, S., Neill, S., Burger, M., Dingledine, J., Gama, V., Sussman, R., Davis, M., Hubbard, L., Budoff, M., Darabian, S., Rezaeian, P., Wong, N., Fox, M., Oudiz, R., Kim, L., Detrano, R., Cruickshanks, K., Bainbridg, K., Lima, J., Bluemke, D., Turkbey, E., Geest, R. J. van der, Liu, C., Malayeri, A., Jain, A., Miao, C., Chahal, H., Jarboe, R., Nathan, D.M., Monnier, V., Sell, D., Strauch, C., Hazen, S., Pratt, A., Tang, W., Brunzell, J., Purnell, J., Purnell, J., Natarajan, R., Miao, F., Zhang, L., Chen, Z., Paterson, A., Boright, A., Bull, S., Sun, L., Scherer, S., Lyons, T.J., Jenkins, A., Klein, R., Virella, G., Jaffa, A., Carter, R., Stoner, J., Garvey, W.T., Lackland, D., Brabham, M., McGee, D., Zheng, D., Mayfield, R. K., Maynard, J., Wessells, H., Sarma, A., Dunn, R., Holt, S., Hotaling, J., Kim, C., Clemens, Q., McVary, Kevin T. , Cuddihy, Robert , Paterson, Andrew D. , Gubitosi-Klug, Rose A , Paterson, Andrew , Zinman, Bernard , Sivitz, William I. , Ziegler, G., Nathan, D.M., Engel, Samuel S. , Reid, M., Genuth, Saul, McConnell, J., Campbell, R., Carey, J.D., Dd, Etzwiler, Cavallerano, Jerry D. , Larkin, M.E., DeManbey, Andrea, Ajroud-Driss, S., Mudaliar, S., Herman, W.H., Pop-Busui, R., Mech, Michael, Schade, D.S., Schwartz, S., Becker, Dj., Arch, J., Shipe, C., Drash, A L, Pavan, P R , DeClue, Terry J., Raskin, P., Rogers, S., Boer, I.H. de, Dupre, J, Tamborlane, W., Gatcomb, P., Bebu, I., Cleary, P., McGee, P., Steffes, M., Arends, V., Bm, Chavers, Polak, J., Feldman, E. L., Nickander, K. K., Pfiefer, M., Dittz, Dalton , Virella, Gabriel, Mayfield, R. K., Brown, Jonathan D. , Cuddihy, Robert M

Mayo Clinic

Diabetes Care | November 15, 2017 | Volume: 40 | Issue: 12 | Pages: 1756-1762

10.2337/dc16-2523 | PMID 29138273 Get It

OBJECTIVE Intensive treatment (INT) of type 1 diabetes reduces the incidence of cardiovascular disease (CVD) events compared with conventional treatment (CONV), but it also results in more weight gain. Our objective was to examine whether excessive weight gain from INT of type 1 diabetes is independently associated with subsequent CVD events. RESEARCH DESIGN AND METHODS Quartiles (Q) of weight gain in 1,213 participants aged 18 years and older at enrollment in the Diabetes Control and Complications Trial (DCCT) were determined within randomized treatment groups (INT vs. CONV) using change in BMI from baseline to the closeout DCCT visits. Effects of this weight gain on CVD risk factors and outcomes during an additional 20 years of observational follow-up were then determined. RESULTS The Q4 INT group experienced greater proportional weight gain (median change in BMI, 6.08 kg/m2), increases in CVD risk factors, and need for medications for hypertension and lipids compared with the Q1–3 INT and comparable CONV groups. Over a mean of 26 years of follow-up, the numbers of major and total CVD events were not statistically different in Q4 compared with Q1–3 of either the INT or CONV group. By year 14, however, the incident CVD event curve became significantly higher in the Q4 INT group than in the Q1–3 INT groups (P = 0.024) and was similar to that for the CONV group. CONCLUSIONS For the first 13 years after DCCT, INT for type 1 diabetes reduced macrovascular events compared with CONV, even when excessive weight gain occurred. After this, total CVD events significantly increased in the Q4 INT group, becoming equivalent to those in the CONV group. Longer follow-up is needed to determine whether this trend continues and results in more major CVD events.
Predictors of Pancreatic Cancer–Associated Weight Loss and Nutritional Interventions
Nemer, Laura, Krishna, Somashekar G. , Shah, Zarine K. , Conwell, Darwin L. , Cruz‐Monserrate, Zobeida , Dillhoff, Mary , Guttridge, Denis C. , Hinton, Alice , Manilchuk, Andrei , Pawlik, Timothy M. , Schmidt, Carl , Talbert, Erin E. , Bekaii‐Saab, Tanios , Hart, Phil A. , Krishna, Somashekar G , Bekaii-Saab, Tanios S , Pawlik, Timothy M

Mayo Clinic

Pancreas | September 11, 2017 | Volume: 46 | Issue: 9 | Pages: 1152-1157

10.1097/mpa.0000000000000898 | PMID 28902785 Get It

Objectives Pancreatic ductal adenocarcinoma (PDAC) is often accompanied by weight loss. We sought to characterize factors associated with weight loss and observed nutritional interventions, as well as define the effect of weight loss on survival. Methods Consecutive subjects diagnosed with PDAC (N = 123) were retrospectively evaluated. Univariate analysis was used to compare subjects with and without substantial (>5%) weight loss. Multivariate logistic regression was performed to identify factors associated with weight loss, and survival analyses were performed using Kaplan-Meier curves and Cox survival models. Results Substantial weight loss at diagnosis was present in 71.5% of subjects and was independently associated with higher baseline body mass index, longer symptom duration, and increased tumor size. Recommendations for nutrition consultation and pancreatic enzyme replacement therapy occurred in 27.6% and 36.9% of subjects, respectively. Weight loss (>5%) was not associated with worse survival on multivariate analysis (hazard ratio, 1.32; 95% confidence interval, 0.76–2.30), unless a higher threshold (>10%) was used (hazard ratio, 1.77; 95% confidence interval, 1.09–2.87). Conclusions Despite the high prevalence of weight loss at PDAC diagnosis, there are low observed rates of nutritional interventions. Weight loss based on current criteria for cancer cachexia is not associated with poor survival in PDAC.
Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers
Javed, Ammar A. , Thoburn, Christopher J. , Wong, Fay , Tie, Jeanne , Allen, Peter J., Schattner, Mark , Petersen, Gloria M. , Hong, Seung‐Mo , Falconi, Massimo , Weiss, Matthew J. , Ahuja, Nita , He, Jin , Makary, Martin A. , Molin, Marco Dal , Li, Lu , Ptak, Janine , Dobbyn, Lisa , Silliman, Natalie , Hruban, Ralph H. , Wolfgang, Christopher L. , Papadopoulos, Nickolas , Kinzler, Kenneth W. , Vogelstein, Bert , Lennon, Anne Marie , Thoburn, Christopher , Javed, Ammar A , Tie, Jeanne , Lennon, Anne Marie , Cohen, Joshua D. , Gibbs, Peter , Schmidt, Christian Max , YIP-SCHNEIDER, Michele T. , Brand, Randall E. , Singhi, Aatur Dilip , Kim, Song Cheol , Doglioni, Claudio , Maitra, Anirban , Hanash, Samir , Wang, Yuxuan , Schaefer, Joy , Popoli, Maria , Goggins, Michael , Klein, Alison P. , Tomasetti, Cristian , Massimo, Falconi

Mayo Clinic

Proceedings of the National Academy of Sciences | September 5, 2017 | Volume: 114 | Issue: 38 | Pages: 10202-10207

10.1073/pnas.1704961114 | PMID 28874546 Get It

Significance Few patients with pancreatic cancer survive longer than 5 y, in part because most patients are identified only after their disease has progressed to an advanced stage. In this study, we show how combining mutations in circulating tumor DNA (ctDNA) with protein markers can result in a screening test with improved sensitivity while retaining specificity. The combination of the ctDNA and protein markers was superior to any single marker. Moreover, the combination detected nearly two-thirds of pancreatic cancers that had no evidence of distant metastasis at the time of surgical resection. The strategy may represent an approach to detect cancers of many types at an earlier stage.
Aquaporin-4 serostatus does not predict response to immunotherapy in neuromyelitis optica spectrum disorders
Schmidt, Felix , López, Reydmar , Arango, J.A. Jiménez, Paul, Friedemann , Wingerchuk, Dean M. , Greenberg, Benjamin , Kim, Ho Jin , Levy, Michael , Levy, Michael , Greenberg, Benjamin M , Paul, Friedemann , Mealy, Maureen A. , Kim, Su‐Hyun

Mayo Clinic

Multiple Sclerosis Journal | August 31, 2017 | Volume: 24 | Issue: 13 | Pages: 1737-1742

10.1177/1352458517730131 | PMID 28857723 Get It

Background: Debate exists about whether neuromyelitis optica spectrum disorder seronegative disease represents the same immune-mediated attack on astrocytic aquaporin-4 as in seropositive disease. Objective: We investigated whether response to common treatments for neuromyelitis optica spectrum disorder differed by serostatus, as assessed by change in annualized relapse rate. Methods: We performed a multicenter retrospective analysis of 245 patients with neuromyelitis optica spectrum disorder who were treated with either rituximab or mycophenolate mofetil as their first-line immunosuppressive treatment for disease prevention. Patients were followed for a minimum of 6 months following treatment initiation. Results: In those started on rituximab, the pre-treatment annualized relapse rates for seropositive and seronegative patients were 1.81 and 1.93, respectively. On-treatment annualized relapse rates significantly declined to 0.32 (seropositive; p < 0.0001) and 0.12 (seronegative; p = 0.0001). In those started on mycophenolate mofetil, the pre-treatment annualized relapse rates for seropositive and seronegative patients were 1.79 and 1.45, respectively. On-treatment annualized relapse rates declined to 0.29 (seropositive; p < 0.0001) and 0.30 (seronegative; p < 0.005). Conclusion: In this international collaboration involving a large number of neuromyelitis optica spectrum disorder patients, treatment was effective regardless of serostatus. This suggests that treatment should not differ when considering these treatments.
Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer
Haricharan, Svasti , Punturi, Nindo , Singh, Purba , Holloway, Kimberly R. , Schmelz, Jacob , Schmidt, Cheryl, Lei, Jonathan T. , Li, Shunqiang , Huang, Shixia , Edwards, Dean P., Kavuri, Shyam M. , Bainbridge, Matthew N. , Cynthia, X. , Suman, Vera, Anurag, Meenakshi , Suman, Vera J. , Hunt, Kelly K. , Olson, John A. , Hoog, Jeremy , Ellis, Matthew J. , Lei, Jonathan T

Mayo Clinic

Cancer Discovery | August 11, 2017 | Volume: 7 | Issue: 10 | Pages: 1168-1183

10.1158/2159-8290.cd-16-1179 | PMID 28801307 Get It

Abstract Significant endocrine therapy–resistant tumor proliferation is present in ≥20% of estrogen receptor–positive (ER+) primary breast cancers and is associated with disease recurrence and death. Here, we uncover a link between intrinsic endocrine therapy resistance and dysregulation of the MutL mismatch repair (MMR) complex (MLH1/3, PMS1/2), and demonstrate a direct role for MutL complex loss in resistance to all classes of endocrine therapy. We find that MutL deficiency in ER+ breast cancer abrogates CHK2-mediated inhibition of CDK4, a prerequisite for endocrine therapy responsiveness. Consequently, CDK4/6 inhibitors (CDK4/6i) remain effective in MutL-defective ER+ breast cancer cells. These observations are supported by data from a clinical trial where a CDK4/6i was found to strongly inhibit aromatase inhibitor–resistant proliferation of MutL-defective tumors. These data suggest that diagnostic markers of MutL deficiency could be used to direct adjuvant CDK4/6i to a population of patients with breast cancer who exhibit marked resistance to the current standard of care. Significance: MutL deficiency in a subset of ER+ primary tumors explains why CDK4/6 inhibition is effective against some de novo endocrine therapy–resistant tumors. Therefore, markers of MutL dysregulation could guide CDK4/6 inhibitor use in the adjuvant setting, where the risk benefit ratio for untargeted therapeutic intervention is narrow. Cancer Discov; 7(10); 1168–83. ©2017 AACR. This article is highlighted in the In This Issue feature, p. 1047
Abstract 489: Mismatch repair defects and endocrine therapy resistance in estrogen receptor positive breast cancer
Haricharan, Svasti , Schmelz, Jacob , Schmidt, Cheryl, Singh, Purba , Holloway, Kimberly R. , Li, Shunqiang , Kavuri, Shyam M. , Huang, Shixia , Edwards, Dean P., Cynthia, X. , Bainbridge, Matthew N. , Anurag, Meenakshi , Suman, Vera J. , Hunt, Kelly K. , Olson, John A. , Hoog, Jeremy , Ellis, Matthew J.

Mayo Clinic

Cancer Research | July 31, 2017 | Volume: 77 | Issue: 13_Supplement | Pages: 489-489

10.1158/1538-7445.am2017-489 Get It

Abstract Estrogen receptor positive (ER+) breast cancer is treated with endocrine therapy but intrinsic resistance occurs in ~1/3 of patients and acquired resistance in ~1/5 of the remainder. While many resistance mechanisms have been explored, therapeutic strategies to overcome resistance in the clinical setting have seen mixed outcomes, and appear most effective in the acquired resistance setting. Understanding mechanisms of resistance and finding therapeutic strategies to target them, therefore, remain important challenges facing breast cancer researchers. In this study we systematically examine the role of DNA damage repair defects in inducing endocrine therapy resistance, a relatively understudied question of recent interest. We use in silico analysis of clinical datasets, in vitro experiments evaluating endocrine therapy resistance in response to DDR dysregulation in multiple breast cancer celllines, and in vivo validation using cellline xenograft and patient-derived xenograft models. We also use gene expression microarrays and RPPA data from cell lines, patient-derived xenografts and primary ER+ breast tumors to uncover therapeutic options that are validated in vitro and in vivo and corroborated by clinical trial data. The results of this study uncover an intriguing link between mismatch repair (MMR) deficiency, specifically of the MutL complex (MLH1/3, PMS1/2), and poor prognosis in ER+ disease. We find a direct role for MutL loss in endocrine therapy resistance in vitro and in vivo by knocking down multiple MutL genes using CRISPR and stable shRNA approaches validated using standard rescue experiments. We identify the underlying mechanism: MutL deficiency in ER+ breast cancer abrogates Chk2-mediated feedback inhibition of CDK4/6 that appears necessary for endocrine therapy responsiveness. Consequently, pharmacological targeting of CDK4/6 in vitro and in vivo significantly inhibits growth of endocrine therapy resistant MutL-deficient ER+ breast cancer cells. These results are corroborated by data from a neoadjuvant clinical trial demonstrating that cell cycle regulation of MutL-mutant tumors tends to be estrogen-independent but sensitive to CDK4/6 inhibitors. The results of this study provide important biological and clinically relevant insights. 1) MMR deficiency is unexpectedly causal to intrinsic endocrine therapy resistance 2) This causal effect appears to be mediated by abrogation of cell cycle checkpoint activation in response to endocrine therapy 3) MMR deficiency in a subset of ER+ tumors explains why CDK4/6 inhibition is effective against some de novo endocrine therapy resistant tumors. While there are currently no biomarkers to guide the use of CDK4/6 inhibitors for ER+ breast cancer, markers of MMR dysregulation could identify patients in whom CDK4/6 inhibition should be used to prevent disease recurrence. Citation Format: Svasti Haricharan, Jacob Schmelz, Cheryl Schmidt, Purba Singh, Kimberly R. Holloway, Meenakshi Anurag, Shunqiang Li, Shyam M. Kavuri, Shixia Huang, Dean P. Edwards, Vera Suman, Kelly Hunt, John A. Olson, Jeremy Hoog, Cynthia X. Ma, Matthew N. Bainbridge, Matthew J. Ellis. Mismatch repair defects and endocrine therapy resistance in estrogen receptor positive breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 489. doi:10.1158/1538-7445.AM2017-489
Abstract 3389: Integrated genomic analyses reveal frequent TERT aberrations in acral melanoma
Hendricks, William P.D. , Kiefer, Jeffrey , Schmidt, Jessica, Sekar, Shobana , Carpten, John D. , Craig, David W. , Adkins, Jonathan, Cuyugan, Lori, Manojlovic, Zarko , Halperin, Rebecca F. , Helland, Adrienne , Legendre, Christophe, Hurley, Laurence H. , Sivaprakasam, Karthigayini , Johnson, Douglas B. , Crandall, Holly , Busam, Klaus J. , Zismann, Victoria , Lee, Jeeyun , Sosman, Jeffrey A. , Trent, Jeffrey M. , Liang, Winnie S. , Nasser, Sara A. , DeLuca, Valerie , Sekulic, Aleksander , Ariyan, Charlotte Eielson

Mayo Clinic

Cancer Research | July 31, 2017 | Volume: 77 | Issue: 13_Supplement | Pages: 3389-3389

10.1158/1538-7445.am2017-3389 Get It

Abstract Genomic analyses of cutaneous melanoma (CM) have yielded biological and therapeutic insights, but understanding of non-ultraviolet (UV)-derived CMs remains limited. Deeper analysis of acral lentiginous melanoma (ALM), a rare sun-shielded melanoma subtype associated with worse survival than CM, is needed to delineate non-UV oncogenic mechanisms. We thus performed comprehensive genomic and transcriptomic analysis of 34 ALM patients. Unlike CM, somatic alterations were dominated by structural variation and absence of UV-derived mutation signatures. Only 38% of patients demonstrated driver BRAF/NRAS/NF1 mutations. Contrasting with CM, we observed PAK1 copy gains in 15% of patients, and somatic TERT translocations, copy gains, and missense and promoter mutations, or germline events, in 41% of patients. We further show that in vitro TERT inhibition has cytotoxic effects on primary ALM cells. These findings provide insight into the role of TERT in ALM tumorigenesis, and reveal preliminary evidence that TERT inhibition represents a potential therapeutic strategy in ALM. Citation Format: Winnie S. Liang, William Hendricks, Jeffrey Kiefer, Jessica Schmidt, Shobana Sekar, John Carpten, David W. Craig, Jonathan Adkins, Lori Cuyugan, Zarko Manojlovic, Rebecca F. Halperin, Adrienne Helland, Sara Nasser, Christophe Legendre, Laurence H. Hurley, Karthigayini Sivaprakasam, Douglas B. Johnson, Holly Crandall, Klaus J. Busam, Victoria Zismann, Valerie De Luca, Jeeyun Lee, Aleksandar Sekulic, Charlotte E. Ariyan, Jeffrey Sosman, Jeffrey Trent. Integrated genomic analyses reveal frequent TERT aberrations in acral melanoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 3389. doi:10.1158/1538-7445.AM2017-3389
Spectral performance of a whole-body research photon counting detector CT: quantitative accuracy in derived image sets
Zhou, Wei , Yu, Zhicong , Halaweish, Ahmed, Krauß, Bernhard , Schmidt, Bernhard , Yu, Lifeng , Kappler, S. , McCollough, C, McCollough, Cynthia, Leng, Shuai , Halaweish, Ahmed, Yu, Lifeng , Zhou, Wei

Mayo Clinic

Physics in Medicine & Biology | July 20, 2017 | Volume: 62 | Issue: 17 | Pages: 7216-7232

10.1088/1361-6560/aa8103 | PMID 28726669 Get It

Abstract Photon-counting computed tomography (PCCT) uses a photon counting detector to count individual photons and allocate them to specific energy bins by comparing photon energy to preset thresholds. This enables simultaneous multi-energy CT with a single source and detector. Phantom studies were performed to assess the spectral performance of a research PCCT scanner by assessing the accuracy of derived images sets. Specifically, we assessed the accuracy of iodine quantification in iodine map images and of CT number accuracy in virtual monoenergetic images (VMI). Vials containing iodine with five known concentrations were scanned on the PCCT scanner after being placed in phantoms representing the attenuation of different size patients. For comparison, the same vials and phantoms were also scanned on 2nd and 3rd generation dual-source, dual-energy scanners. After material decomposition, iodine maps were generated, from which iodine concentration was measured for each vial and phantom size and compared with the known concentration. Additionally, VMIs were generated and CT number accuracy was compared to the reference standard, which was calculated based on known iodine concentration and attenuation coefficients at each keV obtained from the U.S. National Institute of Standards and Technology (NIST). Results showed accurate iodine quantification (root mean square error of 0.5 mgI/cc) and accurate CT number of VMIs (percentage error of 8.9%) using the PCCT scanner. The overall performance of the PCCT scanner, in terms of iodine quantification and VMI CT number accuracy, was comparable to that of EID-based dual-source, dual-energy scanners.